DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clinical trial NCT04920617 · RECRUITING
Trial details
- NCT number
- NCT04920617
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-18
- Primary completion
- 2024-10-01
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.